Skip to main content
Top
Published in: Endocrine 1/2007

01-08-2007 | Original Paper

GLP-1 amplifies insulin signaling by up-regulation of IRβ, IRS-1 and Glut4 in 3T3-L1 adipocytes

Authors: Hong Gao, Xinjun Wang, Zhiguo Zhang, Yisheng Yang, Jun Yang, Xiaoying Li, Guang Ning

Published in: Endocrine | Issue 1/2007

Login to get access

Abstract

Glucagon-like peptide-1 (7–36) amide (GLP-1) is an insulin secretagogue. Recently, many studies have shown GLP-1 can improve insulin resistance in peripheral tissues. In the present study, we investigated glucose uptake in 3T3-L1 adipocytes in either basal or insulin resistant state and dissected insulin signaling pathway in order to elucidate the molecular mechanisms of GLP-1 mediated improvement of insulin resistance. We found GLP-1 and its long lasting analogue, exendin 4 up-regulated basal IR, IRS-1 and Glut 4 expressions although they did not increase basal glucose uptake alone. However, GLP-1 and exendin-4 increased insulin mediated glucose uptake in intact and TNF-α treated 3T3-L1 adipocytes by up-regulation of phophorylated IRβ, IRS-1, Akt and GSK-3β. These results indicate that GLP-1 and its analogue exendin-4 can amplify insulin signaling in 3T3-L1 adipocytes by up-regulation of some crucial insulin signaling molecules.
Literature
4.
go back to reference N. Gonzalez, A. Acitores, V. Sancho et al. Regulat. Peptides 126, 203–211 (2005)CrossRef N. Gonzalez, A. Acitores, V. Sancho et al. Regulat. Peptides 126, 203–211 (2005)CrossRef
10.
14.
go back to reference D.A. Dalessio, R.L. Prigeon, J.W. Ensinck, Diabetes. 44, 1433–1437 (1995)CrossRef D.A. Dalessio, R.L. Prigeon, J.W. Ensinck, Diabetes. 44, 1433–1437 (1995)CrossRef
15.
go back to reference H. Yang, J.M. Egan, Y. Wang et al. Am. J. Physiol. 275, 675–683 (1998) H. Yang, J.M. Egan, Y. Wang et al. Am. J. Physiol. 275, 675–683 (1998)
22.
go back to reference A. Shisheva, J. Buxton, M.P. Czech, J. Biol. Chem. 269, 23865–23868 (1994)PubMed A. Shisheva, J. Buxton, M.P. Czech, J. Biol. Chem. 269, 23865–23868 (1994)PubMed
Metadata
Title
GLP-1 amplifies insulin signaling by up-regulation of IRβ, IRS-1 and Glut4 in 3T3-L1 adipocytes
Authors
Hong Gao
Xinjun Wang
Zhiguo Zhang
Yisheng Yang
Jun Yang
Xiaoying Li
Guang Ning
Publication date
01-08-2007
Publisher
Humana Press Inc
Published in
Endocrine / Issue 1/2007
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-007-9011-4

Other articles of this Issue 1/2007

Endocrine 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.